SÃ©bastien Papot

List of Publications by Year
in descending order

51 papers	1,607 citations	279798 23 h-index	302126 39 g-index
57 all docs	57 docs citations	57 times ranked	1868 citing authors

#	Article	IF	Citations
1	Rotaxaneâ€Based Propeptides: Protection and Enzymatic Release of a Bioactive Pentapeptide. Angewandte Chemie - International Edition, 2009, 48, 6443-6447.	13.8	129
2	A mechanically interlocked molecular system programmed for the delivery of an anticancer drug. Chemical Science, 2015, 6, 2608-2613.	7.4	124
3	Targeting the tumour microenvironment with an enzyme-responsive drug delivery system for the efficient therapy of breast and pancreatic cancers. Chemical Science, 2017, 8, 3427-3433.	7.4	95
4	The First Generation of Î²â€Galactosidaseâ€Responsive Prodrugs Designed for the Selective Treatment of Solid Tumors in Prodrug Monotherapy. Angewandte Chemie - International Edition, 2012, 51, 11606-11610.	13.8	89
5	Î²-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: An update. European Journal of Medicinal Chemistry, 2014, 74, 302-313.	5.5	86
6	Synthesis and Antitumor Efficacy of a Î²-Glucuronidase-Responsive Albumin-Binding Prodrug of Doxorubicin. Journal of Medicinal Chemistry, 2012, 55, 4516-4520.	6.4	64
7	Oxidative decarboxylation of diclofenac by manganese oxide bed filter. Water Research, 2013, 47, 5400-5408.	11.3	61
8	Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates. Chemical Science, 2019, 10, 4048-4053.	7.4	59
9	Second generation specific-enzyme-activated rotaxane propeptides. Chemical Communications, 2012, 48, 2083.	4.1	50
10	Cyanuric chloride: an efficient reagent for the Lossen rearrangement. Tetrahedron Letters, 2009, 50, 6800-6802.	1.4	47
11	Controlled Release of a Micelle Payload via Sequential Enzymatic and Bioorthogonal Reactions in Living Systems. Angewandte Chemie - International Edition, 2019, 58, 6366-6370.	13.8	45
12	First O-Glycosylation of Hydroxamic Acids. Journal of Organic Chemistry, 2007, 72, 4262-4264.	3.2	39
13	Synthesis and biological evaluation of the suberoylanilide hydroxamic acid (SAHA) Î²-glucuronide and Î²-galactoside for application in selective prodrug chemotherapy. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 983-986.	2.2	39
14	Rotaxane-based architectures for biological applications. Comptes Rendus Chimie, 2016, 19, 103-112.	0.5	39
15	Development and evaluation of Î²-galactosidase-sensitive antibody-drug conjugates. European Journal of Medicinal Chemistry, 2017, 142, 376-382.	5.5	38
16	Synthesis and biological evaluation of glucuronide prodrugs of the histone deacetylase inhibitor CI-994 for application in selective cancer chemotherapy. Bioorganic and Medicinal Chemistry, 2008, 16, 8109-8116.	3.0	37
17	A self-immolative dendritic glucuronide prodrug of doxorubicin. MedChemComm, 2012, 3, 68-70.	3.4	37
18	The Lossen rearrangement from free hydroxamic acids. Organic and Biomolecular Chemistry, 2019, 17, 5420-5427.	2.8	34

#	Article	IF	Citations
19	Volatile Organic Compound Based Probe for Induced Volatolomics of Cancers. Angewandte Chemie - International Edition, 2019, 58, 17563-17566.	13.8	31
20	A new cyclopamine glucuronide prodrug with improved kinetics of drug release. Organic and Biomolecular Chemistry, 2011, 9, 8459.	2.8	25
21	A Heterodimeric Glucuronide Prodrug for Cancer Tritherapy: the Double Role of the Chemical Amplifier. ChemMedChem, 2011, 6, 2137-2141.	3.2	25
22	A Galactosidaseâ€Responsive â€œTrojan Horseâ€•for the Selective Targeting of Folate Receptorâ€Positive Tumor Cells. ChemMedChem, 2011, 6, 1006-1010.	3.2	24
23	Reductionâ€“rebridging strategy for the preparation of ADPN-based antibodyâ€“drug conjugates. MedChemComm, 2018, 9, 827-830.	3.4	24
24	Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy. European Journal of Medicinal Chemistry, 2013, 67, 75-80.	5.5	23
25	Bioorthogonal Reactions in Animals. ChemBioChem, 2021, 22, 100-113.	2.6	22
26	A Î²-glucuronidase-responsive albumin-binding prodrug for potential selective kinase inhibitor-based cancer chemotherapy. European Journal of Medicinal Chemistry, 2018, 158, 1-6.	5.5	21
27	An enzyme-responsive system programmed for the double release of bioactive molecules through an intracellular chemical amplification process. Organic and Biomolecular Chemistry, 2013, 11, 7129.	2.8	19
28	A new spacer group derived from arylmalonaldehydes for glucuronylated prodrugs. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 2545-2548.	2.2	18
29	Selective Release of a Cyclopamine Glucuronide Prodrug toward Stem-like Cancer Cell Inhibition in Glioblastoma. Molecular Cancer Therapeutics, 2014, 13, 2159-2169.	4.1	18
30	Evaluation of Cytotoxic Properties of a Cyclopamine Glucuronide Prodrug in Rat Glioblastoma Cells and Tumors. Journal of Molecular Neuroscience, 2015, 55, 51-61.	2.3	18
31	In vivo synthesis of triple-loaded albumin conjugate for efficient targeted cancer chemotherapy. Journal of Controlled Release, 2020, 327, 19-25.	9.9	17
32	Study of a cyclopamine glucuronide prodrug for the selective chemotherapy of glioblastoma. European Journal of Medicinal Chemistry, 2010, 45, 1678-1682.	5.5	15
33	A galactosidase-responsive doxorubicin-folate conjugate for selective targeting of acute myelogenous leukemia blasts. Leukemia Research, 2013, 37, 948-955.	0.8	15
34	A dendritic Î²-galactosidase-responsive folateâ€“monomethylauristatin E conjugate. Chemical Communications, 2015, 51, 15792-15795.	4.1	15
35	Diastereoselective synthesis of [1]rotaxanes via an active metal template strategy. Chemical Science, 2021, 12, 2521-2526.	7.4	15
36	A Î²-glucuronidase-responsive albumin-binding prodrug programmed for the double release of monomethyl auristatin E. MedChemComm, 2018, 9, 2068-2071.	3.4	14

#	Article	IF	Citations
37	Synthesis and cytotoxic activity of a glucuronylated prodrug of nornitrogen mustard. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 1835-1837.	2.2	12
38	Controlled Release of a Micelle Payload via Sequential Enzymatic and Bioorthogonal Reactions in Living Systems. Angewandte Chemie, 2019, 131, 6432-6436.	2.0	11
39	Cellâ€“cell interactions via non-covalent click chemistry. Chemical Science, 2021, 12, 9017-9021.	7.4	11
40	A new simple and convenient method for the synthesis of substituted 2,6,9-trioxabicyclo[3.3.1]-nona-3,7-dienes from arylmalondialdehydes. Tetrahedron Letters, 2006, 47, 5961-5964.	1.4	7
41	In situ targeted activation of an anticancer agent using ultrasound-triggered release of composite droplets. European Journal of Medicinal Chemistry, 2017, 142, 2-7.	5.5	7
42	Enzymeâ€Cleavable Linkers for Protein Chemical Synthesis through Solidâ€Phase Ligations. Angewandte Chemie - International Edition, 2021, 60, 18612-18618.	13.8	7
43	Development of an embedded multimodality imaging platform for onco-pharmacology using a smart anticancer prodrug as an example. Scientific Reports, 2020, 10, 2661.	3.3	6
44	Dietary docosahexaenoic acid proposed to sensitize breast tumors to locally delivered drug. Clinical Lipidology, 2010, 5, 233-243.	0.4	5
45	Monitoring glycosidase activity for clustered sugar substrates, a study on Î²-glucuronidase. RSC Advances, 2019, 9, 40263-40267.	3.6	5
46	Volatile Organic Compound Based Probe for Induced Volatolomics of Cancers. Angewandte Chemie, 2019, 131, 17727-17730.	2.0	3
47	Absolute configuration of a [1]rotaxane determined from vibrational and electronic circular dichroism spectra. Chirality, 2021, 33, 773-782.	2.6	2
48	Enzymeâ€Cleavable Linkers for Protein Chemical Synthesis through Solidâ€Phase Ligations. Angewandte Chemie, 2021, 133, 18760-18766.	2.0	1
49	Inside Cover: A Heterodimeric Glucuronide Prodrug for Cancer Tritherapy: the Double Role of the Chemical Amplifier (ChemMedChem 12/2011). ChemMedChem, 2011, 6, 2114-2114.	3.2	0
50	Innentitelbild: The First Generation of Î²-Galactosidase-Responsive Prodrugs Designed for the Selective Treatment of Solid Tumors in Prodrug Monotherapy (Angew. Chem. 46/2012). Angewandte Chemie, 2012, 124, 11556-11556.	2.0	0
51	A Î²-Cyclodextrin-Albumin Conjugate for Enhancing Therapeutic Efficacy of Cytotoxic Drugs. Bioconjugate Chemistry, 2022, 33, 1138-1144.	3.6	0